Hyperuricemia is a risk factor for cardiovascular risk?

Venkata Krisnan, Bhimasen Soren, K. Ramalingam, M. Prasad Naidu, Akhil G., Meghana Chegireddy


Background: Uric acid is the end product of purine metabolism in humans degraded by the hepatic enzyme, urate oxidase (uricase), to allantoin, which is freely excreted in the urine. However, during the Miocene epoch (20 to 5 million years ago), 2 parallel but distinct mutations occurred in early hominoids that rendered the uricase gene non-functional. Uric acid (UA) is a known endogenous scavenger, which provides a major part of the antioxidant capacity against oxidative and radical injury.

Methods: The present study was conducted over a period of one year on outpatients attending the General Medicine Department at Narayana General Hospital, Nellore. The study was included 998 subjects (500 male and 498 female) and authors excluded other complications. Data were analyzed by SPSS software.

Results: Serum uric acid of the subjects were measured. The mean and standard deviation were calculated for all the Biochemical parameter. The significance between the groups was determined using Student t-test for equality of means. The two-tailed P value is less than 0.0001, which is statistically significant. Confidence interval: the hypothetical mean is 1.0000 and the actual mean is 6.4600. The difference between these two values is 5.4600. The 95% confidence interval of this difference from 5.3489 to 5.5711. Intermediate values used in calculations; t = 96.4583, df = 999 and standard error of difference p = 0.057.

Conclusions: About 53% of the subjects of the study are hyperuricemia, with about 74% of these subjects (or about 39% of the total) diagnosed with hypertension or diabetes mellitus or both, indicating a high CVD risk.


Antioxidant, Cardiovascular disease, Hyperuricemia, Uric acid

Full Text:



Johnson RJ, Lanaspa MA, Gaucher EA. Uric acid: A danger signal from the RNA world that may have a role in the epidemic of obesity, metabolic syndrome, and cardiorenal disease: evolutionary considerations. Semin Nephrol. 2011;31(5):394.

Vassalle C, Mazzone A, Sabatino L, Carpeggiani C. Uric acid for cardiovascular risk: Dr. Jekyll or Mr. Hide?. Dis. 2016;4(1):12.

Hosoya T, Nishio S. Asymptomatic hyperuricemia. J General Family Med. 2016;17(1):71-6.

Yokokawa H, Fukuda H, Suzuki A, Fujibayashi K, Naito T, Uehara Y, et al. Association between serum uric acid levels/hyperuricemia and hypertension among 85,286 Japanese workers. J Clinic Hypertens. 2016;18(1):53-9.

Lee JJ, Ahn J, Hwang J, Han SW, Lee KN, Kim JB, et al. Relationship between uric acid and blood pressure in different age groups. Clinic Hypertens. 2015;21(1):14.

Cui LF, Shi HJ, Wu SL, Shu R, Liu N, Wang GY, et al. Association of serum uric acid and risk of hypertension in adults: a prospective study of Kailuan Corporation cohort. Clinic Rheumatol. 2017;36(5):1103-10.

Yu FN, Shi YX, Cheng HY, Huang XL, Liu SS. An observational study on the relationship between serum uric acid and hypertension in a Northern Chinese population aged 45 to 59 years. Med. 2017;96(17).

Mazzali M, Kanbay M, Segal MS, Shafiu M, Jalal D, Feig DI, et al. Uric acid and hypertension: cause or effect?. Current Rheumatol Reports. 2010;12(2):108-17.

Dawson J, Wyss A. Chicken or the egg? Hyperuricemia, insulin resistance, and hypertension. Hypertens. 2017;70(4):698-9.

Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertens. 2001;38(5):1101-6.

Simão AN, Lozovoy MA, Dichi I. The uric acid metabolism pathway as a therapeutic target in hyperuricemia related to metabolic syndrome. Expert Opinion Therap Target. 2012;16(12):1175-87.

Mortada I. Hyperuricemia, type 2 diabetes mellitus, and hypertension: an emerging association. Curr Hypertens Reports. 2017;19(9):69.

Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nature Reviews Nephrol. 2005;1(2):80.

Han T, Lan L, Qu R, Xu Q, Jiang R, Na L, et al. Temporal relationship between hyperuricemia and insulin resistance and its impact on future risk of hypertension. Hypertens. 2017;70(4):703-11.

Kuwabara M, Kuwabara R, Hisatome I, Niwa K, Roncal‐Jimenez CA, Bjornstad P, et al. Metabolically healthy obesity and hyperuricemia increase risk for hypertension and diabetes:5‐year Japanese Cohort Study. Obesit. 2017;25(11):1997-2008.

Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertens. 2003;41(6):1183-90.

Suliman ME, Johnson RJ, García-López E, Qureshi AR, Molinaei H, Carrero JJ, et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis. 2006;48(5):761-71.

Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Therapy. 2006;8(1):S4.

Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric acid and the development of metabolic syndrome in women and men. Metabol. 2008;57(6):845-52.

Pilger E, Pristautz H, Pfeiffer KP, Kostner G. Risk factors for peripheral atherosclerosis. Retrospective evaluation by stepwise discriminant analysis. Arteriosclerosis: an official J Am Heart Assoc, Inc. 1983;3(1):57-63.

Schmidt MI, Watson RL, Duncan BB, Metcalf P, Brancati FL, Sharrett AR, et al. Atherosclerosis risk in communities study investigators. Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Metabol. 1996;45(6):699-706.

Bonora E. The metabolic syndrome and cardiovascular disease. Annals Med. 2006;38(1):64-80.

Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. New England J Med. 2008;359(17):1811-21.

Majid A, Aslam S, Babar MZ. Hyperuricemia: a predictor of in hospital complications in acute coronary syndrome patients. Age (years). 2017;56(12):62-11.

Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis s. 2006;47(1):51-9.